IP Library › Granted Patent US 11,679,116
Granted Patent B2
US 11,679,116 · App. 17/366,871 · Granted Jun 20, 2023

Topical compositions and methods for treating psoriasis

Inventors: Gordon J. Dow (Greenbrae, CA); Radhakrishnan Pillai (Santa Rosa, CA); Varsha D. Bhatt (San Francisco, CA)
Assignee: Bausch Health Ireland Limited
A61K31/573A61K9/0014A61K9/06A61K9/107A61K9/12A61K31/192A61K31/4436A61K45/06A61K47/14A61K47/26A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,679,116
App. No.
17/366,871
Granted
Jun 20, 2023
Kind
B2
Abstract

Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.

Claims (15)

1. A pharmaceutical composition consisting essentially of:

tazarotene, 0.045% w/w,

diethyl sebacate, 2.97% w/w,

light mineral oil, 8.03% w/w,

sorbitan monooleate, 0.1% w/w,

sorbitol solution (70%), 10.7% w/w,

methyl paraben, 0.17% w/w,

propyl paraben, 0.03% w/w,

edetate disodium dihydrate, 0.05% w/w,

carbomer copolymer type B, 0.4% w/w,

carbomer homopolymer type A, 0.6% w/w,

sodium hydroxide, q.s. to pH of 5.5±0.5, and

purified water, q.s. to 100% w/w;

wherein the composition is a lotion.

2. A method of treating psoriasis, the method comprising topically applying a pharmaceutical composition of claim 1 to an affected area of a body of a subject suffering from psoriasis; wherein said applying is carried out one or more times per day for a period of time sufficient to treat such psoriasis.

Assignments (14)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2025
From: BARCLAYS BANK PLC
To: BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH COMPANIES INC.
Reel/Frame 070830/0577 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2022
From: BAUSCH HEALTH US, LLC
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 060038/0057 →
SECURITY INTEREST Recorded Nov 24, 2021
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH+LOMB IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 058205/0889 →
SECURITY INTEREST Recorded Nov 24, 2021
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH+LOMB IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; SOLTA MEDICAL IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 058205/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2021
From: DOW, GORDON J.; PILLAI, RADHAKRISHNAN; BHATT, VARSHA D.
To: VALEANT PHARMACEUTICALS NORTH AMERICA LLC
Reel/Frame 056749/0166 →
CHANGE OF NAME Recorded Jul 3, 2021
From: VALEANT PHARMACEUTICALS NORTH AMERICA LLC
To: BAUSCH HEALTH US, LLC
Reel/Frame 056759/0880 →